ArticleFrontiers in pharmacology2025
Exploring the molecular mechanisms of huperzine a in the treatment of rosacea through network pharmacology, machine learning, and molecular dynamics simulations.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring the Effects and Mechanisms of Neohesperidin Dihydrochalcone on Acute Lung Injury in Mice with Sepsis Using Network Pharmacology and Machine Learning.Current issues in molecular biology · 2026Article
- Machine learning-assisted network pharmacology reveals that the Chaihu-Longgu-Muli decoction modulates the inflammatory microenvironment to treat perimenopausal syndrome.Frontiers in molecular biosciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rosacea is a common chronic inflammatory skin disorder and dysregulation of neuroimmune functions and neurovascular loops play critical roles in the development of rosacea. Huperzine A (Hup A) has several bioactive properties, including anti-inflammatory, antioxidant, and neuroprotective effects. However, the potential roles of Hup A in treating rosacea is unknown. Methods: Network pharmacology, molecular docking, and molecular dynamics simulation techniques has been used to investigate the anti-rosacea mechanisms of Hup A in rosacea. Results: Our results predicted 21 potential anti-rosacea targets of Hup A through public databases. KEGG pathway enrichment analysis revealed that these key targets participated in the regulation of MAPK signaling, NF-kappa B signaling, and PI3KAKT signaling pathways. Further machine learning analysis identified six core targets (BCL2, RXRA, PKN2, XDH, PRKCA, and FAP). Analysis of the GSE65914 dataset showed that XDH was upregulated in rosacea lesions, while BCL2 and RXRA were downregulated, with no significant expression changes of the other genes. Molecular docking results indicated that Hup A could bind to key targets (XDH, BCL2, and RXRA), which were further confirmed by molecular dynamics simulations. Discussion: This study systematically elucidates the potential mechanisms of Hup A in the treatment of rosacea and provides a theoretical basis for its application in rosacea therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.